PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Trends Neurosci. Author manuscript; available in PMC 2010 October 14.
Published in final edited form as:
PMCID: PMC2954610
NIHMSID: NIHMS238421

Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics

Abstract

Axon-guidance-pathway molecules are involved in connectivity and repair throughout life (beyond guiding brain wiring during fetal development). One study found that variations (single-nucleotide polymorphisms [SNPs]) in axon-guidance-pathway genes were predictive of three Parkinson’s disease (PD) outcomes (susceptibility, survival free of PD and age at onset of PD) in genome-wide association (GWA) datasets. The axon-guidance-pathway genes DCC, EPHB1, NTNG1, SEMA5A and SLIT3 were represented by SNPs predicting PD outcomes. Beyond GWA analyses, we also present relevant neurobiological roles of these axon-guidance-pathway molecules and consider mechanisms by which abnormal axon-guidance-molecule signaling can cause loss of connectivity and, ultimately, PD. Novel drugs and treatments could emerge from this new understanding.

Introduction

Brain function is based on precise neuronal-network formation during development, which is largely controlled by attractive and repulsive axon-guidance molecules [1]. The spatially and temporally regulated expression of the guidance cues navigates the outgrowth of axons and specifies their termination zones and synaptic partners [2,3]. Many guidance molecules persist in the adult central nervous system and extensive studies have shown that these factors have roles in maintenance and plasticity of neural circuits [4]. Such factors also participate in adult brain repair and regeneration after brain injury [4]. Emerging evidence indicates that guidance molecules could also have important roles in neurodegenerative disorders owing to altered signaling during development and/or owing to altered maintenance of synaptic connections in the adult. There is some neuropathological evidence of misrouted fibers in the adult human brain, and in Parkinson disease (PD) and Alzheimer’s disease [5].

PD is primarily a movement disorder characterized by resting tremor, bradykinesia, rigidity and postural instability. The pathological underpinnings of these motor symptoms include a marked degeneration of dopamine (DA) neurons in the substantia nigra (SN), with resultant striatal DA deficiency. The lifetime risk for PD in the general population is 2% [6] and the incidence of PD rises steeply with age [7]. Presently, there is no method of preventing PD or of halting its progression. However, a method of predicting PD was recently reported [8]. This genomic pathway approach involved measuring common variations (single-nucleotide polymorphisms [SNPs]) within a family of genes that encode the wiring of the brain during fetal development and that encode the maintenance and repair of brain wiring throughout life (the axon-guidance pathway). The additive effects of these variants (SNP models) were highly predictive of PD susceptibility, survival free of PD and age at onset of PD in two independent genome-wide association (GWA) datasets. Several axon-guidance-pathway genes represented by SNPs in the predictive models were differentially expressed in a genome-wide expression profiling dataset. SNP models for PD were subsequently refined and compared with axon-guidance-pathway SNP models that were highly predictive of amyotrophic lateral sclerosis (ALS) [9]. Distinct gene signatures for the two diseases were defined within the pathway, and ultimately these diseases could be predicted with >90% sensitivity and specificity. However, the findings for the axon-guidance pathway and ALS await validation in a second GWA dataset.

Here, we summarize axon-guidance-pathway SNP models for PD outcomes in two GWA datasets and also describe the roles and mechanisms involved in the actions of these specific axon-guidance-pathway genes or gene products as candidate targets for neuroprotective therapies. We also summarize experimental data for PD, relevant DA neurons and their connected target neurons as rationales for these therapeutic targets.

Axon-guidance-pathway SNP models nominate therapeutic targets for PD

A GWA study of PD mapped the semaphorin 5A (SEMA5A) gene as a susceptibility locus for PD [10] and, thus, high-lighted a possible role for axon guidance in the pathogenesis of PD. Although disease associations for single SNPs have small effects and are difficult to replicate, additive effects of SNPs within functionally related genes could have large effects and replicate across studies.

We have summarized the convergence of results for the predictive SNP models for recorded clinical outcomes in two GWA datasets (Table 1). There are five axon-guidance-pathway genes that were represented by SNPs in all of the models: deleted in colorectal carcinoma (DCC), ephrin receptor B1 (EPHB1), netrin-G1 (NTNG1), SEMA5A and SLIT3. However, it is noteworthy that four of the five genes did not have informative probe sets (not expressed) and one gene (EPHB1) was expressed similarly in PD cases and controls (Table 1). This raises the intriguing possibility that the mechanism by which these genes contribute to PD is temporally remote from the clinical terminal state, such as early degenerative changes in the years preceding diagnosis and possibly even during brain development (this is called the miswiring hypothesis).

Table 1
Classic axon-guidance molecules associate with genetic risk for PDa

Although such a selection of candidate targets is based on the convergence of final SNP models within two independent samples, several models of SNPs predicted PD outcomes in those samples [8,9]. However, it should be pointed out that Li et al. [11] could not replicate such conclusions from their sample data, possibly because different axon-guidance-pathway SNP models will be predictive of PD in other samples and not the final models highlighted (i.e. locus heterogeneity) [11]. By contrast, two other studies performed pathway-based analyses of three GWA datasets of PD combined and concluded that axon guidance was significantly associated with PD susceptibility and ranked at or near the top of several hundred pathways in two of the three datasets [12,13]. In the following description, we illustrate possible mechanisms by which variability in axon-guidance-pathway genes might contribute to the pathogenesis of PD.

Neurobiological basis of axon-guidance pathways as therapeutic targets for PD

The axon-guidance pathway consists of four major classes of ligands (ephrin, netrin, semaphorin and slit proteins), their respective receptors (e.g. eph, DCC and unc, neuropilin and plexin, and robo proteins) and several downstream signaling proteins. Together, these chemical signals provide a series of attraction and repulsion cues that direct axons to their targets. A diagram of these processes can be found in the Kyoto Encyclopedia of Genes and Genomes (KEGG) (www.genome.jp/kegg/pathway/hsa/hsa04360.html). For each major class of ligands and receptors, axon-guidance-pathway SNP-based models nominated a therapeutic target (Table 1) and each such molecule is discussed in a neurobiological context later.

Netrin

Secreted netrins (netrin-1 to netrin-4) and their receptors are one of the well-characterized axon-guidance-pathway families [14]. Netrins can bind to DCC or Unc6/Unc5 receptors [15], exhibiting attractive and repulsive activities in the axon guidance, respectively. In the midbrain DA system, netrin-1 protein enhances DA axonal outgrowth and functions as an attractant of DA axons. Such effects were mediated by the DCC receptor as demonstrated by antibody blockade [16]. The association of this ligand–receptor family to the pathogenesis of PD has been modeled in Netrin-1-null mice, which display a loss of DA neurons and mislocalized and mistargeted DA neurons in the nigrostriatal tract during development*. DCC-deficient adult mice show altered DA transmission and locomotor activity accompanied by reduced dendritic-spine density in the cerebral cortex [17]. These findings demonstrate that DCC is a crucial molecule in the development of DA circuitry formation, and alterations in the DCC levels can lead to cognitive and behavioral abnormalities in the adulthood. Netrin-1 also defines the structural organization of the striatum, which determines the synaptic formation of DA afferents [18]. In addition to its role in the neuronal connectivity, netrin-1, DCC and UNC5 also mediate neuronal survival that involves the PIKE-L-stimulated phosphatidylinositol 3-kinase cascade [19]. Some SNP models indicate that variability in the DCC gene, and possibly in UNC5-encoding genes, predicts PD outcomes (Table 1). A potential outcome of altered function of secreted netrin-1 and its receptors, which would possibly disorganize synaptic circuitry and alter DA transmission, would then increase susceptibility for individuals to develop PD.

Netrin-G1 and netrin-G2 (NTNGs) are glycosyl-phosphatidylinositol-anchored membrane proteins [20,21]. Unlike netrin-1, they are not secreted ligands but anchored ligands and they do not bind to the DCC or Unc5 receptors but to netrin-G ligands (NGLs) [21,22]. This subgroup of netrin proteins contains multiple alternatively spliced isoforms that are expressed in the developing brain and in the adult brain [20,21,23]. Lack of orthologs of these genes in Caenorhabditis elegans or Drosophila melanogaster indicates a specific role in the brain function of vertebrates. Mutations in the NTNG1 gene cause an atypical presentation of Rett Syndrome with epileptic seizures of early onset [24,25]. Postmortem studies have demonstrated differential expression of NTNG1 in schizophrenia [26,27]. Rett syndrome, epilepsy and schizophrenia are disorders attributed to impaired synaptic formation, functioning and plasticity within glutamate and γ-aminobutyric acid (GABA)-transmitting neurons [2831]. Indeed, experiments demonstrate that NTNG–NGL ligand–receptor pairs function as synaptic cell-adhesion molecules that regulate synapse formation and maintenance [20,21,32]. NGLs contain an intracellular PDZ (postsynaptic density [PSD]-95/disc large/zona occludens-1)-binding domain that interacts with the PSD-95 family of proteins to modulate the formation of excitatory synapses [22]. Overexpression of NGL2 increases the number of PSD-95-positive dendritic protrusions, and NGL2 aggregation leads to clustering of postsynaptic proteins including NR2A (NMDA receptors), indicating that NTNG–NGL adhesion proteins partner with PSD-95 to recruit PSD-95-associated postsynaptic proteins for excitatory synapse differentiation [22]. By contrast, NGL2 inhibition or NGL2 silencing via small interfering RNA reduces the number of excitatory synapses and current potentials [22]. It is known that NGL1 is abundantly expressed in the striatum and that glutamatergic synapses are selectively depleted in PD models [22,23,33]. Some SNP models indicate that variability in the NTNG1 gene predicts PD outcomes (Table 1). Given these genetic and biological findings, it is possible that differential expression of NTNG1 alters dopaminergic and glutamatergic circuitry and, thus, contributes to pathogenesis of PD (Figure 1). However, such mechanisms of developmental (i.e. miswiring) or lifelong (i.e. impaired axon maintenance, repair and synaptic plasticity) structural changes require further study.

Figure 1
Axon-guidance molecules: ligands and receptors on pre- and post-connective elements in neural circuitry. The drawing shows a simplified model of synaptic disconnection and repair associated with axon-guidance molecules (axon in blue; dendrite in yellow; ...

Slit

Expression of slits and robos (also known as ‘roundabout’) occurs in concert with the development of midbrain DA neuronal pathway formation. Their complementary regional distribution of slits and robos indicate both structural and functional roles in nigrostriatal and striatonigral pathways [34]. Indeed, it has been shown that loss of Slit1 and Slit2 expression results in an abnormal course of the nigrostriatal pathway through the diencephalon [35]. These mutant mice also exhibit errors in the projection of the nigrostriatal pathway in the striatum*. Whether DA axonal mistargting caused by SLIT1 and/or SLIT2 gene deficiency during development will lead to aberrant DA function in the adult remains to be determined. One set of bioinformatic analyses of SNPs indicated that variability in the SLIT3 gene, and possibly in other SLIT and ROBO genes, predicts PD outcomes (Table 1). SLIT3 mRNA expression is absent in the embryonic striatum but abundant in the adult striatum [34]. SLIT3 knockout influences diaphragm and kidney development but no brain deficits have been reported [36]. However, Slit3 expression is upregulated after spinal cord injury and might be inhibitory for the regenerating axons [37]. The secretion and function of Slit3 is largely unknown, particularly in the DA system. Nonetheless, it has been reported that Slit3 is localized in the mitochondria and its expression can be induced by lipopolysaccharide (LPS) [38]. As a result, Slit3 stimulates cell motility of macrophages, indicating that Slit3 is involved in a LPS-induced inflammatory response that could contribute to PD pathogenesis [39]. The Slit/robo pathway also mediates signals of cell degeneration and tissue remodeling [40]. Given these functional roles of Slit3, it is possible that the Slit3/robo pathway might initiate and accelerate PD processes or progression.

Ephrin

In EPHB1-knockout mice, there is a significant cell loss in the SN pars reticulata, but there is no obvious change in the number of DA neurons in the SN pars compacta [41]. The mice displayed spontaneous locomotor hyperactivity [41]. It has also been noted that EPHA5 (EPH receptor A5)-knockout mice developed neurochemical and behavioral deficits including impaired striatal function, as assessed by an active-avoidance paradigm [42]. These observations indicate a role for ephrin/eph signaling in the structure and connectivity of the dopaminergic pathway. However, this signaling is likely to involve multiple members from the EphA and EphB receptor subfamilies with many potential interactions. Because the ephrin/eph family has a variety of important functions including axonal outgrowth and pruning, neuronal connectivity, synaptic maturation and plasticity, and neuronal apoptosis [2,4345] it is plausible that variability in such molecules could contribute to the initiation and progression of neurodegenerative diseases. Several SNP models indicate that variability in the EPHB1 gene, and possibly in other EPH-ligand and EPH-receptor genes, predicts PD outcomes (Table 1). In addition, it was recently suggested that mutations in the vesicle-associated membrane protein B (VAPB) gene cause ALS in families via the ligand-binding effects of the miscoded protein on its eph receptors [46]. Axon-guidance-pathway models for ALS pathology include SNPs in several ephrin and eph receptor genes, and the EFNA5 and EPHB1 genes are represented by SNPs in final models for all three outcomes proposed in one study to date (ALS susceptibility, survival free of ALS and age at onset of ALS) [9]. However, the findings for axon-guidance-pathway SNP models in ALS require validation using individual-level genotyping data from other GWA study datasets (as yet, not publicly available).

Semaphorin

Systematic meta-analysis has confirmed that variability in the plexin A2 (PLXNA2) gene is associated with susceptibility to schizophrenia, another disorder characterized by aberrant DA transmission [47]. One set of SNP models indicates that variability in the SEMA5A gene, and possibly in other SEMA-ligand and PLXN-receptor genes, also predicts PD outcomes (Table 1). However, some new groups have challenged the genetic association of SEMA5A with PD risk. Clarimon et al. [48] conducted a gene-association study in two independent case-control series of patients from Finland and Taiwan. They found in the Taiwanese, but not in the Finnish, cohort an associated risk of SEMA5A in the locus as reported by Maraganore et al. [10] in patients from Minnesota. Another group [49] could not confirm that SEMA5A is a risk-conferring gene in a Polish and an Asian population. These discrepancies might have resulted from the use of different cohorts and genetic heterogeneity. Although that is interesting in itself, and probably reflects different genetic variations in separate populations (and genetic maps and/or methods used), independent replication across populations should be conducted to clarify the role of carrying SNP variation in this gene and the risk for developing PD. How could sema5A increase susceptibility of PD? Sema5A is a membrane-bound protein and interacts with receptor of plexin B3 [50]. Sema5A-null mice die at E11.5 and E12.5 owing to defects in cranial vascular system and blood vessels [51]. It is known that sema5A is expressed in the cerebral cortex, basal ganglia, thalamus and other regions in rat brain [52]. During development, sema5A functions as an attractive and repulsive guidance molecule, and altered expression has been linked with aberrant development of axonal connections in the forebrain [53,54]. In the adult brain, it has been shown that sema5A expression in the glial cells inhibits axon growth by retinal ganglion cells after injury [55]. Furthermore, it has been shown that haploinsufficiency for sema5A is involved in mental retardation in Cri-du-chat, a disorder caused by deletions of chromosome 5p where sema5A resides [56]. Another genetic study of autism indicates that sema5A is a candidate gene in the etiology of idiopathic autism in which synaptic dysfunction of specific neurons play a part in the disease development [57]. Importantly, it has been known that several members of the semaphorin family participate in various phases of immune responses, from initiation to terminal inflammatory processes, and therefore are also called ‘immune semaphorins’ [58]. Sema5A is one of the molecules that interact with forebrain embryonic zinc finger-like (FEZL), and that interaction induces genes related with immune response including tumor necrosis factor-α and interleukin-8 expression. The FEZL–sema5A pathway increases susceptibility of cow to mastitis [59]. Overall, these studies indicate that sema5A exhibits multiple functions in axonal connection and regeneration, vascular development and the immune system. Altered expression of sema5A is associated with some brain disorders and infectious diseases. These data also provide reasons to examine how the variability of sema5A could be involved in increasing the risk of PD by causing dysfunction of synaptic activity and inflammation. The latter can sensitize the response of DA neurons to endogenous and exogenous insults [39,60].

Can new therapies be accomplished by modifying structural connectivity and growth processes in the adult brain?

In summary, using genomic pathway analyses and available neurobiological and medical data, several molecules involved in axon-guidance-pathway formation seem to be relevant to PD [8]. Such genetic variability in the axon-guidance pathway might result in developmental defects in brain wiring [35,61,62] and/or in lifelong defects in axon maintenance, repair and synergistic connectivity [63,64], which could contribute to the pathogenesis and dysfunction seen in PD. Given that directional guidance cues persist in the adult brain (as evidenced by target seeking of axons of transplanted fetal cells to distant and specific adult host neurons; Figure 2), chemorepulsive and chemoattractive molecules are clearly present in the adult brain [65,66]. Furthermore, mechanistic studies to define how variations in genes such as DCC, EPHB1, NTNG1, SEMA5A and SLIT3 predispose to PD could further expand an understanding of PD and other degenerative brain disorders. In the future, connectivity-controlling molecules could be targeted therapeutically for the purposes of enhancing reconnection or repairing neuronal pathways [6668].

Figure 2
Evidence of selective and appropriate neuro- and chemotropism in the normal adult brain. Drawings and photomicrographs illustrating axonal-growth patterns from cross-species fetal ventral midbrain cell transplants into adult rats. Diagrams (a) and (b) ...

Acknowledgments

This work was supported by a National Institutes of Health grant (P50NS39793; www.nih.gov), the Michael Stern Foundation (www.parkinsoninfo.org), the Orchard Foundation, the Consolidated Anti-Aging Foundation, and the Harold and Ronna Cooper Family (O.I.) and by funds from a National Institutes of Health grant (R01ES10751), a Michael J. Fox Foundation Linked Efforts to Accelerate Parkinson’s Solutions award (www.michaeljfox.org) and a Mayo Clinic Discovery-Translation Program award (D.M.M.; www.mayoclinic.com).

Footnotes

*Li, J. et al. (2007) Netrin 1 and Slit 1/2 are required for correct localization of midbrain dopaminergic cell bodies and targeting of their axons [abstract] Soc. Neurosci. 460.4/E36.

References

1. Tessier-Lavigne M, Goodman CS. The molecular biology of axon guidance. Science. 1996;274:1123–1133. [PubMed]
2. Lim BK, et al. Ephrin-B reverse signaling promotes structural and functional synaptic maturation in vivo. Nat Neurosci. 2008;11:160–169. [PubMed]
3. Wu Z, et al. Caenorhabditis elegans neuronal regeneration is influenced by life stage, ephrin signaling, and synaptic branching. Proc Natl Acad Sci U S A. 2007;104:15132–15137. [PubMed]
4. Curinga G, Smith GM. Molecular/genetic manipulation of extrinsic axon guidance factors for CNS repair and regeneration. Exp Neurol. 2008;209:333–342. [PMC free article] [PubMed]
5. Hoogland PV, et al. Misrouted olfactory fibres and ectopic olfactory glomeruli in normal humans and in Parkinson and Alzheimer patients. Neuropathol Appl Neurobiol. 2003;29:303–311. [PubMed]
6. Elbaz A, et al. Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol. 2002;55:25–31. [PubMed]
7. Bower JH, et al. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson’s disease. Mov Disord. 2000;15:819–825. [PubMed]
8. Lesnick TG, et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet. 2007;3:e98. [PubMed]
9. Lesnick TG, et al. Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathway. PLoS One. 2008;3:e1449. [PMC free article] [PubMed]
10. Maraganore DM. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet. 2005;77:685–693. [PubMed]
11. Li Y, et al. Neither replication nor simulation supports a role for the axon guidance pathway in the genetics of Parkinson’s disease. PLoS One. 2008;3:e2707. [PMC free article] [PubMed]
12. Wang K, et al. Pathway-based approaches for analysis of Genomewide Association Studies. Am J Hum Genet. 2007;81:1278–1283. [PubMed]
13. Srinivasan BS, et al. Whole genome survey of coding SNPs reveals a reproducible pathway determinant of Parkinson disease. Hum Mutat. ( www.interscience.wiley.com) [PMC free article] [PubMed] [Cross Ref]
14. Moore SW, et al. Netrins and their receptors. Adv Exp Med Biol. 2007;621:17–31. [PubMed]
15. Keleman K, Dickson BJ. Short- and long-range repulsion by the Drosophila Unc5 netrin receptor. Neuron. 2001;32:605–617. [PubMed]
16. Lin L, et al. Netrin-1 and slit-2 regulate and direct neurite growth of ventral midbrain dopaminergic neurons. Mol Cell Neurosci. 2005;28:547–555. [PubMed]
17. Grant A, et al. Netrin-1 receptor-deficient mice show enhanced mesocortical dopamine transmission and blunted behavioural responses to amphetamine. Eur J Neurosci. 2007;26:3215–3228. [PubMed]
18. Hamasaki T, et al. A role of netrin-1 in the formation of the subcortical structure striatum: repulsive action on the migration of late-born striatal neurons. J Neurosci. 2001;21:4272–4280. [PubMed]
19. Tang X, et al. Netrin-1 mediates neuronal survival through PIKE-L interaction with the dependence receptor UNC5B. Nat Cell Biol. 2008;10:698–706. [PMC free article] [PubMed]
20. Nakashiba T, et al. Complementary expression and neurite outgrowth activity of netrin-G subfamily members. Mech Dev. 2002;111:47–60. [PubMed]
21. Yin Y, et al. Laminets: laminin- and netrin-related genes expressed in distinct neuronal subsets. Mol Cell Neurosci. 2002;19:344–358. [PubMed]
22. Kim S, et al. NGL family PSD-95-interacting adhesion molecules regulate excitatory synapse formation. Nat Neurosci. 2006;9:1294–1301. [PubMed]
23. Meerabux JM, et al. Human netrin-G1 isoforms show evidence of differential expression. Genomics. 2005;86:112–116. [PubMed]
24. Archer HL, et al. NTNG1 mutations are a rare cause of Rett syndrome. Am J Med Genet A. 2006;140:691–694. [PMC free article] [PubMed]
25. Nectoux J, et al. Netrin G1 mutations are an uncommon cause of atypical Rett syndrome with or without epilepsy. Pediatr Neurol. 2007;37:270–274. [PubMed]
26. Eastwood SL, Harrison PJ. Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder. Neuropsychopharmacology. 2008;33:933–945. [PMC free article] [PubMed]
27. Fukasawa M, et al. Case-control association study of human netrin G1 gene in Japanese schizophrenia. J Med Dent Sci. 2004;51:121–128. [PubMed]
28. Frankle WG, et al. The synaptic hypothesis of schizophrenia. Neuron. 2003;39:205–216. [PubMed]
29. Johnston MV, et al. Rett syndrome and neuronal development. J Child Neurol. 2005;20:759–763. [PubMed]
30. Johnston MV, et al. Neurobiology of Rett syndrome. J Child Neurol. 2003;18:688–692. [PubMed]
31. Stephan KE, et al. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry. 2006;59:929–939. [PubMed]
32. Nakashiba T, et al. Netrin-G1: a novel glycosyl phosphatidylinositol-linked mammalian netrin that is functionally divergent from classical netrins. J Neurosci. 2000;20:6540–6550. [PubMed]
33. Day M, et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci. 2006;9:251–259. [PubMed]
34. Marillat V, et al. Spatiotemporal expression patterns of slit and robo genes in the rat brain. J Comp Neurol. 2002;442:130–155. [PubMed]
35. Bagri A, et al. Slit proteins prevent midline crossing and determine the dorsoventral position of major axonal pathways in the mammalian forebrain. Neuron. 2002;33:233–248. [PubMed]
36. Yuan W, et al. A genetic model for a central (septum transversum) congenital diaphragmatic hernia in mice lacking Slit3. Proc Natl Acad Sci U S A. 2003;100:5217–5222. [PubMed]
37. Wehrle R, et al. Expression of netrin-1, slit-1 and slit-3 but not of slit-2 after cerebellar and spinal cord lesions. Eur J Neurosci. 2005;22:2134–2144. [PubMed]
38. Tanno T, et al. Slit3 regulates cell motility through Rac/Cdc42 activation in lipopolysaccharide-stimulated macrophages. FEBS Lett. 2007;581:1022–1026. [PubMed]
39. Koprich JB, et al. Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson’s disease. J Neuroinflammation. 2008;5:8. [PMC free article] [PubMed]
40. Dickinson RE, et al. Novel regulated expression of the SLIT/ROBO pathway in the ovary: possible role during luteolysis in women. Endocrinology. 2008;149:5024–5034. [PubMed]
41. Richards AB, et al. EphB1 null mice exhibit neuronal loss in substantia nigra pars reticulata and spontaneous locomotor hyperactivity. Eur J Neurosci. 2007;25:2619–2628. [PubMed]
42. Halladay AK, et al. Neurochemical and behavioral deficits consequent to expression of a dominant negative EphA5 receptor. Brain Res Mol Brain Res. 2004;123:104–111. [PubMed]
43. Depaepe V, et al. Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature. 2005;435:1244–1250. [PubMed]
44. Gao PP, et al. Ephrin-dependent growth and pruning of hippocampal axons. Proc Natl Acad Sci U S A. 1999;96:4073–4077. [PubMed]
45. Xu Q, Wilkinson DG. Eph-related receptors and their ligands: mediators of contact dependent cell interactions. J Mol Med. 1997;75:576–586. [PubMed]
46. Tsuda H, et al. The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell. 2008;133:963–977. [PMC free article] [PubMed]
47. Allen NC, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40:827–834. [PubMed]
48. Clarimon J, et al. Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. Am J Hum Genet. 2006;78:1082–1084. [PubMed]
49. Bialecka M, et al. Polymorphism in semaphorin 5A (Sema5A) gene is not a marker of Parkinson’s disease risk. Neurosci Lett. 2006;399:121–123. [PubMed]
50. Artigiani S, et al. Plexin-B3 is a functional receptor for semaphorin 5A. EMBO Rep. 2004;5:710–714. [PubMed]
51. Fiore R, et al. Inactivation of the Sema5a gene results in embryonic lethality and defective remodeling of the cranial vascular system. Mol Cell Biol. 2005;25:2310–2319. [PMC free article] [PubMed]
52. Skaliora I, et al. Differential patterns of semaphorin expression in the developing rat brain. Eur J Neurosci. 1998;10:1215–1229. [PubMed]
53. Kantor DB, et al. Semaphorin 5A is a bifunctional axon guidance cue regulated by heparan and chondroitin sulfate proteoglycans. Neuron. 2004;44:961–975. [PubMed]
54. Jones L, et al. Pax6 is required for the normal development of the forebrain axonal connections. Development. 2002;129:5041–5052. [PubMed]
55. Goldberg JL, et al. An oligodendrocyte lineage-specific semaphorin, Sema5A, inhibits axon growth by retinal ganglion cells. J Neurosci. 2004;24:4989–4999. [PubMed]
56. Simmons AD, et al. Molecular cloning and mapping of human semaphorin F from the Cri-du-chat candidate interval. Biochem Biophys Res Commun. 1998;242:685–691. [PubMed]
57. Melin M, et al. Constitutional downregulation of SEMA5A expression in autism. Neuropsychobiology. 2006;54:64–69. [PMC free article] [PubMed]
58. Suzuki K, et al. Semaphorins and their receptors in immune cell interactions. Nat Immunol. 2008;9:17–23. [PubMed]
59. Sugimoto M, et al. Evidence that bovine forebrain embryonic zinc finger-like gene influences immune response associated with mastitis resistance. Proc Natl Acad Sci U S A. 2006;103:6454–6459. [PubMed]
60. Gao HM, et al. Neuroinflammation and oxidation/nitration of α-synuclein linked to dopaminergic neurodegeneration. J Neurosci. 2008;28:7687–7698. [PMC free article] [PubMed]
61. Kawano H, et al. Aberrant trajectory of ascending dopaminergic pathway in mice lacking Nkx2.1. Exp Neurol. 2003;182:103–112. [PubMed]
62. Sieber BA, et al. Disruption of EphA/ephrin-a signaling in the nigrostriatal system reduces dopaminergic innervation and dissociates behavioral responses to amphetamine and cocaine. Mol Cell Neurosci. 2004;26:418–428. [PubMed]
63. Figueroa JD, et al. Inhibition of EphA7 up-regulation after spinal cord injury reduces apoptosis and promotes locomotor recovery. J Neurosci Res. 2006;84:1438–1451. [PubMed]
64. Shirvan A, et al. Induction of neuronal apoptosis by Semaphorin3A-derived peptide. Brain Res Mol Brain Res. 2000;83:81–93. [PubMed]
65. Harel NY, Strittmatter SM. Can regenerating axons recapitulate developmental guidance during recovery from spinal cord injury? Nat Rev Neurosci. 2006;7:603–616. [PMC free article] [PubMed]
66. Inoue H, et al. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson’s disease models. Proc Natl Acad Sci U S A. 2007;104:14430–14435. [PubMed]
67. Isacson O, Deacon T. Neural transplantation studies reveal the brain’s capacity for continuous reconstruction. Trends Neurosci. 1997;20:477–482. [PubMed]
68. Isacson O, Deacon TW. Specific axon guidance factors persist in the adult brain as demonstrated by pig neuroblasts transplanted to the rat. Neuroscience. 1996;75:827–837. [PubMed]
69. Fung HC, et al. Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2006;5:911–916. [PubMed]
70. Papapetropoulos S, et al. Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson’s disease. Gene Expr. 2006;13:205–215. [PubMed]